65,437 trials
Gastrostomy Complications
Primary: Number of Participants Satisfied With Current Dressings — 3; 3; 5; 5 Participants
Stage III Prostate Adenocarcinoma AJCC v7 · Stage III Prostate Cancer AJCC v7 · Stage IV Prostate Adenocarcinoma AJCC v7
Primary: Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment — 1 Participants
Dry Eye · Dry Eye Syndromes
Primary: Ocular Surface Tear Breakup Time — 3.81; 2.91 seconds — p=<0.01
Osteoarthritis · Acetaminophen · Arthroplasty, Hip Replacement
Primary: 24 Hour Opioid Consumption — 3.0; 3.4 morphine milliequivalent
Bacterial Infections · Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003
Postural Kyphosis, Thoracic Region
Primary: Thoracic Kyphosis Angle — 39.2; 38.9; 27.9; 28.2 degrees — p=<0.001
Barotrauma;Ear · OME - Otitis Media With Effusion · AOM - Acute Otitis Media
Primary: Subject-reported Pain Score Following Tube Delivery System (TDS) Tube Placement Using the Visual Analogue Scale (VAS) by Subject Compared to a Performance Goal. — 9.4…
Cataract
Primary: Rate of Severe Visual Distortions — 189; 142; 0; 2 Participants
Bradyarrhythmia
Primary: Ease of Implant — 6.9; 6.3 score on a scale
Advanced Solid Tumors
Primary: Treatment Phase Part A: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for E7820 — 12500; 11500 nanogram*hour per milliliter (ng*hr/mL)
Rheumatoid Arthritis
Primary: Percentage of Participants Classified as Having Made an Informed Decision at 6 Months — 59.7; 44.2; 49.2; 55.8 percentage of participants — p=0.8408
Ulcerative Colitis
Primary: Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8 — 10; 17 Participants — p=0.039
Curative Breast Cancer Surgery · Inflammatory Positive/Negative Status · Pre Surgical Incision Administration
Primary: Recurrence-free Survival — 80; 96 Participants
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Urothelial Cancer
Primary: Progression-Free Survival — 3.35; 3.02 Months — p=0.31